8-KEarnings & ResultsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 18, 2007)

Filed April 18, 2007For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K on April 18, 2007, to report its first-quarter 2007 financial results. The filing primarily furnishes a press release detailing these results, which includes both GAAP and non-GAAP financial measures. Management utilizes these non-GAAP measures, which exclude items like merger-related costs, purchase accounting adjustments, and restructuring charges, to provide a clearer view of ongoing business performance and facilitate internal monitoring. Investors are advised to consider these non-GAAP figures alongside, not as a replacement for, GAAP-based financial information. The press release, designated as Exhibit 99.1, is the core content of this filing, offering specific operational and financial condition updates for the period. Thomas C. Freyman, Executive Vice President, Finance and Chief Financial Officer, signed the report.

Key Highlights

  • 1Abbott Laboratories announced its Q1 2007 results of operations via an 8-K filing.
  • 2The filing incorporates a press release (Exhibit 99.1) containing the detailed financial results.
  • 3Abbott presented both GAAP and non-GAAP financial measures in its Q1 2007 earnings announcement.
  • 4Non-GAAP measures exclude items such as merger costs, purchase accounting, restructuring charges, litigation, and regulatory impacts.
  • 5Management believes non-GAAP measures offer investors a better evaluation of ongoing business performance.
  • 6Investors are cautioned to consider non-GAAP measures in addition to, and not as a substitute for, GAAP measures.
  • 7The filing was signed by Thomas C. Freyman, EVP, Finance and CFO.

Frequently Asked Questions

The primary purpose of this 8-K filing is to announce and furnish Abbott Laboratories' results of operations for the first quarter of 2007, as detailed in an accompanying press release.

Abbott's non-GAAP financial measures adjust for items that are considered unusual or unpredictable. These include, but are not limited to, merger-related costs, purchase accounting adjustments, restructuring and impairment charges, certain litigation charges, and the impact of changes in laws and regulations.

Investors should interpret Abbott's non-GAAP financial measures as supplementary information that helps evaluate ongoing business performance. However, they are cautioned to consider these measures in addition to, and not as a substitute for, the financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP).

The detailed financial results are provided in the press release dated April 18, 2007, which is furnished as Exhibit 99.1 to this 8-K filing and incorporated by reference.